Shuttle Pharmaceuticals Holdings (SHPH) Non-Current Assets (2021 - 2026)
Shuttle Pharmaceuticals Holdings (SHPH) posted quarterly Non-Current Assets of $9.3 million for Q1 2026, up 2564.36% year-over-year from $350793.0 in Q1 2025, and down 6.28% quarter-over-quarter from $10.0 million in Q4 2025.
Shuttle Pharmaceuticals Holdings (SHPH) Non-Current Assets (2021 - 2026) Analysis & Trends
Shuttle Pharmaceuticals Holdings' Non-Current Assets history runs 6 years deep, the most recent figure standing at $9.3 million for Q1 2026.
- In Q1 2026, Non-Current Assets rose 2564.36% year-over-year to $9.3 million; the TTM figure through Mar 2026 stood at $19.9 million (up 1448.07% YoY), while the FY2025 annual figure was $10.0 million, up 3276.43% from the prior year.
- Non-Current Assets for Q1 2026 stood at $9.3 million, down from $10.0 million in the prior quarter.
- The five-year high for Non-Current Assets was $10.0 million in Q4 2025, with the low at $64616.0 in Q1 2023.
- The 5-year median for Non-Current Assets is $327665.0 (2024), against an average of $1.5 million.
- The sharpest annual moves came in 2022 and 2025: Non-Current Assets sank 47.06% in 2022, then surged 3276.43% in 2025.
- Shuttle Pharmaceuticals Holdings' Non-Current Assets stood at $75194.0 in 2022, then surged by 377.07% to $358731.0 in 2023, then retreated by 17.66% to $295373.0 in 2024, then soared by 3276.43% to $10.0 million in 2025, then retreated by 6.28% to $9.3 million in 2026.
- Business Quant data shows SHPH's Non-Current Assets at $9.3 million in Q1 2026, $10.0 million in Q4 2025, and $277014.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.91 Bn | 42.95 Bn | - | 37.96 Bn |
| 2 | Teva Pharmaceutical Industries | 42.98 Bn | 39.32 Bn | 2.15 Bn | 26.10 Bn |
| 3 | Zoetis | 31.53 Bn | 29.86 Bn | 1.05 Bn | 8.72 Bn |
| 4 | Takeda Pharmaceutical | 28.61 Bn | 22.81 Bn | 5.10 Bn | 78.51 Bn |
| 5 | United Therapeutics | 22.16 Bn | 19.49 Bn | 683.80 Mn | 3.74 Bn |
| 6 | Viatris | 18.74 Bn | 17.85 Bn | 1.46 Bn | 24.99 Bn |
| 7 | Neurocrine Biosciences | 15.51 Bn | 15.12 Bn | 935.80 Mn | 3.72 Bn |
| 8 | Elanco Animal Health | 11.76 Bn | 11.23 Bn | 798.00 Mn | 9.76 Bn |
| 9 | Dr Reddys Laboratories | 10.12 Bn | 9.95 Bn | - | 2.96 Bn |
| 10 | Shuttle Pharmaceuticals Holdings | 1.91 Mn | 1.91 Mn | - | 9.35 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 9.35 Mn |
| Dec 31, 2025 | 9.97 Mn |
| Sep 30, 2025 | 277,014.00 |
| Jun 30, 2025 | 312,512.00 |
| Mar 31, 2025 | 350,793.00 |
| Dec 31, 2024 | 295,373.00 |
| Sep 30, 2024 | 312,217.00 |
| Jun 30, 2024 | 327,665.00 |
| Mar 31, 2024 | 342,902.00 |
| Dec 31, 2023 | 358,731.00 |
| Sep 30, 2023 | 380,210.00 |
| Jun 30, 2023 | 393,759.00 |
| Mar 31, 2023 | 64,616.00 |
| Dec 31, 2022 | 75,194.00 |
| Sep 30, 2022 | 92,530.00 |
| Dec 31, 2021 | 142,026.00 |